-

1 Day Event on Patent Protection for Software-Related Inventions in Europe and the USA (London, United Kingdom - September 25, 2020) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Patent Protection for Software-Related Inventions in Europe and the USA" conference has been added to ResearchAndMarkets.com's offering.

An intensive update on patent protection for software-related inventions covering all the major developments in European patent law in particular GUI inventions and mixed' inventions with both patentable and non-patentable subject matter

Course overview

Technology and software have influences across most business sectors in relation to leveraging growth, and this has important implications for IP and patent laws. This intensive one-day event will help you to understand the development strategies impacting software patents and update you on the major developments in European patent law, in particular, GUI inventions and mixed' inventions with both patentable and non-patentable subject matter.

Under the guidance of our expert faculty, you will learn how recent US case law impacts software patents in the US and become proficient in exploiting the differences between the US and Europe regarding the scope of available patent protection. The course will provide a review of key tactics for US practice and give you an understanding of the latest US strategies in dealing with obviousness and the rise of indefiniteness and written description issues.

Having an experienced in-house lawyer on the faculty will ensure that you benefit from his practical knowledge on selecting and protecting software technologies and get invaluable insights into foreign filing strategies.

You will get to grips with how to avoid pitfalls in claim drafting using case studies and understand whether patent protection should be available for software-related and business-related inventions. A practical workshop session will provide ample opportunity for discussion with the expert faculty and consolidate your learning.

Agenda:

Patent Protection for software-related and business-related inventions in Europe

  • Review of European law relating to the protection of software-related and business-related inventions
  • Review of EPO Board of Appeal decisions including most recent decisions

Patent Protection for software-related and business-related inventions in the United States

  • Update on recent Federal Circuit decisions impacting software
  • Patent practice in the wake of the US Supreme Court's Alice decision
  • Detailed analysis of USPTO's post- Alice guidelines
  • Case examples and claim techniques for US practice
  • Post-grant considerations for these technologies

Preparation of patent applications and prosecution of European applications for software-related and business-related inventions

  • Available claim formats and description requirements in Europe
  • Drafting applications to take account of European and US requirements
  • Filing strategies
  • Dealing with EPO objections under Article 52(1) EPC

Industry view: an in-house perspective on managing IP protection of software-related inventions

  • Selecting what software technologies to patent or to protect in other ways
  • Foreign filing strategies that balance budget and likelihood of success for software innovations
  • Challenges facing companies involved in managing software patents and responsible for software-related technologies

Workshop - Questions, answers and discussion of specific examples

  • An interactive session designed to apply earlier discussion to practical situations
  • Examples and approaches for protecting software and computer-related innovations, taking into account the unique requirements in the US and Europe

For more information about this conference visit https://www.researchandmarkets.com/r/eb80cw

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Ireland Buy Now Pay Later Business and Investment Report 2026: Market to Grow by Over 25% to Reach $446.5 Million - Forecasts to 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Ireland Buy Now Pay Later Business and Investment Opportunities Databook - 90+ KPIs on BNPL Market Size, End-Use Sectors, Market Share, Product Analysis, Business Model, Demographics - Q1 2026 Update" report has been added to ResearchAndMarkets.com's offering. The BNPL payment market in Ireland is expected to grow by 25.5% on annual basis to reach US$446.5 million in 2026. The buy now pay later market in the country has experienced robust growth during 2022-2025, a...

Indonesia Buy Now Pay Later Business and Investment Report 2026: Market to Grow by 22.2% to Reach $11.15 Billion this Year - Forecasts to 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Indonesia Buy Now Pay Later Business and Investment Opportunities Databook - 90+ KPIs on BNPL Market Size, End-Use Sectors, Market Share, Product Analysis, Business Model, Demographics - Q1 2026 Update" report has been added to ResearchAndMarkets.com's offering. The BNPL payment market in Indonesia is expected to grow by 22.2% on annual basis to reach US$11.15 billion in 2026. The buy now pay later market in the country has experienced robust growth during 2022-202...

Cell and Gene Therapy Investment Trends Strategic Intelligence Report 2025: Market to Reach $63 Billion by 2031 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Strategic Intelligence: Cell and Gene Therapy Investment Trends" report has been added to ResearchAndMarkets.com's offering. The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion. CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT products include Gilead Sciences' Yescarta (axicabtagene ciloleucel) and Novartis's Zolgensma (onasemnogene abeparvovec) which reported sales o...
Back to Newsroom